Ruxolitinib generic?

Ruxolitinib is a prescription medication that inhibits Janus‐kinase 1 and 2 (JAK1/2) and is mainly used for conditions such as myelofibrosis, polycythemia vera, and certain inflammatory disorders.

Brand name

• Jakafi (the only brand name that has been approved in the United States, Europe, Canada, and many other countries).
  
  

Generic availability

• Generics exist in many regions. For example:
  
  • In the EU and UK, the generic is sold under the same generic name “ruxolitinib.”
    
  • In Canada, the generic is available and often priced lower than the brand.
    
  • In some Asian markets (e.g., Japan, South Korea), generics are also marketed.
    
    The generic formulation contains the same active ingredient (ruxolitinib) in the same dosage strengths (10 mg and 15 mg tablets) and has the same indications, dosing schedule, and safety profile as Jakafi.
    
    

Why use a generic?

• Cost: Generics are typically 30‑70 % cheaper than the brand‑name product.
  
• Accessibility: Some insurance plans or national formularies prefer or cover the generic version first.
  
• Efficacy & safety: Approved generics must meet the same FDA/EU regulatory standards for bioequivalence and purity.
  
  

Things to keep in mind

• Prescription only: You must have a doctor’s prescription and the medication must be dispensed by a licensed pharmacy.
  
• Monitoring: Ruxolitinib requires routine blood counts and liver function tests, whether you’re on the brand or generic.
  
• Drug interactions: It can interact with CYP3A4 inhibitors/inducers and certain antifungals or antibiotics, so inform your prescriber about all medications you’re taking.
  
  If you’re considering switching from Jakafi to a generic, discuss it with your healthcare provider to ensure the pharmacy you choose is reputable and that the generic meets all regulatory standards in your country.